Earnings ·
Interpace Biosciences reported second quarter 2026 revenue of $9.1 million, reflecting a 9% year-over-year increase on…
IDXGInterpace Biosciences, Inc.
Interpace Biosciences reported second quarter 2026 revenue of $9.1 million, reflecting a 9% year-over-year increase on a pro forma basis after excluding its discontinued PancraGEN business. The company generated income from continuing operations of $0.3 million and Adjusted EBITDA of $0.7 million, with gross margins expanding to 62%. Thyroid test volume grew 6% while average revenue per test increased 3%. Additionally, the firm announced it will appoint a Chief Scientific Officer effective September 8, 2026, to lead scientific strategy and clinical development for its pancreatic cancer program. Interpace Biosciences operates in the molecular diagnostics industry, specializing in thyroid cancer testing through its ThyGeNEXT and ThyraMIR platforms.